SBRT vs. EBRT in treatment of painful spine metastases

New data on this topic — from a Phase II/III clinical trial — have just been presented at the virtual annual meeting of the American Society for Radiation Oncology (ASTRO). Basically, the data from this study by Sahgal et al. indicated that 24 Gy (in two 12 Gy doses) of stereotactic body radiation therapy (SBRT) was more effective in the elimination of spinal pain in patients with metastatic cancer as compared to 20 Gy (in five 4 Gy doses) of conventional, external beam radiation therapy (EBRT).

… READ MORE …

Adding ADT to external beam radiation only benefits unfavorable risk patients

In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …

RP vs. RT as first-line treatment for prostate cancer: that word “may” again

A newly published commentary on the CancerNetwork web site is entitled, “Radical prostatectomy as primary treatment for prostate cancer leads to better survival.” … READ MORE …

Importance of adding ADT to brachy boost therapy for men with unfavorable-risk prostate cancer

Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …

Long-term adjuvant ADT improves results of brachy-boost therapy in unfavorable-risk prostate cancer patients

TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …

Radiation therapy for prostate cancer in the time of COVID-19

A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients. … READ MORE …

“Adjuvant” similar to “early salvage” radiation outcome in meta-analysis

Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …

The first-line treatment of locally advanced prostate cancer (clinical stage T3)

Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …

SABR to oligometastases slows progression via immune response

Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …

Adjuvant chemotherapy does NOT improve BDFS rates in men with intermediate- and high-risk prostate cancer

With the third Advanced Prostate Cancer Consensus Conference (APCCC) due to start here in Basel, Switzerland, this morning, there is an important new set of data that will help to inform some of the discussions. … READ MORE …

Evidence for dose escalation in adjuvant/salvage radiation

It is well known that prostate cancer is relatively radio-resistant compared to other kinds of cancer. … READ MORE …

Is whole pelvic radiation needed for primary treatment of Gleason 9/10 prostate cancer?

Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …

Should SBRT be THE preferred treatment for intermediate-risk prostate cancer?

Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …

SBRT: the optimal dose

While excellent outcomes of stereotactic body radiation therapy (SBRT) have been reported since it was first used to treat prostate cancer in 2003, the delivered doses have ranged from 35 Gy in five treatments to 40 Gy in five treatments. … READ MORE …

How to get a free gallium-68 PSMA-11 PET/CT scan (and yes, there IS a catch)

A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …